Monoamine transporter availability in Parkinson's disease patients with or without depression

被引:69
|
作者
Hesse, Swen [1 ]
Meyer, Philipp M. [1 ]
Strecker, Karl [2 ]
Barthel, Henryk [1 ]
Wegner, Florian [2 ]
Oehlwein, Christian [3 ]
Isaias, Ioannis Ugo [2 ]
Schwarz, Johannes [2 ]
Sabri, Osama [1 ]
机构
[1] Univ Leipzig, Dept Nucl Med, D-04103 Leipzig, Germany
[2] Univ Leipzig, Dept Neurol, D-04103 Leipzig, Germany
[3] Specialized Parkinsons Dis Outpatient Ctr, Gera, Germany
关键词
SPECT; Dopamine; Serotonin; Striatum; Midbrain; POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN TRANSPORTERS; STRIATAL DOPAMINE; NEUROPSYCHIATRIC SYMPTOMS; I-123-FP-CIT SPECT; LIMBIC SYSTEM; BETA-CIT; BINDING; IMPAIRMENT; BRAIN;
D O I
10.1007/s00259-008-0979-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Depression is a common symptom in patients suffering from Parkinson's disease (PD) and markedly reduces their quality of life. As post-mortem studies have shown, its presence may reflect extensive cell loss in the midbrain and brainstem with imbalances in monoaminergic neurotransmitters. However, in vivo evidence of specific monoaminergic deficits in depressed PD patients is still sparse. Therefore, we studied PD patients with depression (PD+D) and without depression (PD-D) using high-resolution single-photon emission computed tomography (SPECT) and the monoamine transporter marker [I-123]FP-CIT. A magnetic resonance imaging-based region-of-interest analysis was applied to quantify the specific-to-nondisplaceable [I-123]FP-CIT binding coefficient V(3)aEuro(3) in the striatum, thalamus and midbrain/brainstem regions. PD+D patients had significantly lower V(3)aEuro(3) compared with PD-D patients in the striatum (p < 0.001), thalamus (p=0.002), and midbrain/brainstem (p=0.025). Only PD+D patients without selective serotonin reuptake inhibitor (SSRI) treatment showed lower thalamic and midbrain V(3)aEuro(3) than controls (p < 0.001, p=0.029). In a small sub-group of SSRI-treated PD+D patients neither thalamic V(3)aEuro(3) nor midbrain/brainstem V(3)aEuro(3) differed from those in PD-D patients (p=0.168, p=0.201) or controls (p=0.384, p=0.318). Our data indicate that depression in PD is associated with a more pronounced loss of striatal dopamine transporter availability that is most likely secondary to increased dopaminergic degeneration. In addition, depressed PD patients have a lower availability of midbrain/brainstem monoamine transporters than nondepressed PD patients. These findings provide in vivo evidence in support of the known post-mortem data demonstrating more extensive nerve cell loss in PD with depression and indicate that SPECT imaging can help to identify pathophysiological changes underlying nonmotor symptoms in this common movement disorder.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 50 条
  • [21] Serotonin transporter binding and anxiety symptoms in Parkinson's disease
    Joling, Merijn
    van den Heuvel, Odile A.
    Berendse, Henk W.
    Booij, Jan
    Vriend, Chris
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (01) : 89 - 94
  • [22] Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment
    Thobois, Stephane
    Prange, Stephane
    Sgambato-Faure, Veronique
    Tremblay, Leon
    Broussolle, Emmanuel
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (10)
  • [23] Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease
    Choi, HJ
    Lee, SY
    Cho, Y
    Hwang, OY
    NEUROCHEMISTRY INTERNATIONAL, 2005, 46 (04) : 329 - 335
  • [24] Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease
    Smith, Gwenn S.
    Mills, Kelly A.
    Pontone, Greg M.
    Anderson, W. Stanley
    Perepezko, Kate M.
    Brasic, James
    Zhou, Yun
    Brandt, Jason
    Butson, ChristopirR.
    Holt, Daniel P.
    Mathews, William B.
    Dannals, Robert F.
    Wong, Dean F.
    Mari, Zoltan
    PARKINSONISM & RELATED DISORDERS, 2019, 64 : 235 - 241
  • [25] Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and parkinsonism secondary to carbon monoxide poisoning
    Hsiao, Ing-Tsung
    Chang, Yu-Tzu
    Weng, Yi-Hsin
    Hsu, Shih-Wei
    Lin, Kun-Ju
    Lu, Chin-Song
    Chang, Chiung-Chih
    NEUROTOXICOLOGY, 2022, 88 : 178 - 186
  • [26] Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease
    Chou, Kelvin L.
    Dayalu, Praveen
    Koeppe, Robert A.
    Gilman, Sid
    Spears, C. Chauncey
    Albin, Roger L.
    Kotagal, Vikas
    MOVEMENT DISORDERS, 2022, 37 (11) : 2301 - 2307
  • [27] Role of Serotonergic 1A Receptor Dysfunction in Depression Associated with Parkinson's Disease
    Ballanger, Benedicte
    Klinger, Helene
    Eche, Julien
    Lerond, Jerome
    Vallet, Anne-Evelyne
    Le Bars, Didier
    Tremblay, Leon
    Sgambato-Faure, Veronique
    Broussolle, Emmanuel
    Thobois, Stephane
    MOVEMENT DISORDERS, 2012, 27 (01) : 84 - 89
  • [28] Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders
    Bruecke, Thomas
    Bruecke, Christof
    JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (5-6) : 581 - 594
  • [29] Minor depression and brain perfusion images in Parkinson's disease
    Matsui, Hideaki
    Nishinaka, Kazuto
    Oda, Masaya
    Komatsu, Kenichi
    Kubori, Tamotsu
    Udaka, Fukashi
    MOVEMENT DISORDERS, 2006, 21 (08) : 1169 - 1174
  • [30] Depression in Parkinson's Disease: The Contribution from Animal Studies
    Fontoura, Jessica Lopes
    Baptista, Camila
    Pedroso, Flavia de Brito
    Pochapski, Jose Augusto
    Miyoshi, Edmar
    Ferro, Marcelo Machado
    PARKINSONS DISEASE, 2017, 2017